Cencora, Inc. $COR Shares Sold by Copperleaf Capital LLC

Copperleaf Capital LLC decreased its holdings in shares of Cencora, Inc. (NYSE:COR) by 5.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,385 shares of the company’s stock after selling 277 shares during the period. Copperleaf Capital LLC’s holdings in Cencora were worth $1,219,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Price T Rowe Associates Inc. MD boosted its holdings in Cencora by 8.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock valued at $2,682,821,000 after purchasing an additional 787,858 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Cencora by 7.2% in the first quarter. Wellington Management Group LLP now owns 5,421,262 shares of the company’s stock valued at $1,507,599,000 after buying an additional 363,402 shares in the last quarter. Boston Partners boosted its stake in shares of Cencora by 8.1% in the first quarter. Boston Partners now owns 5,411,193 shares of the company’s stock valued at $1,505,984,000 after buying an additional 404,093 shares in the last quarter. Invesco Ltd. grew its holdings in Cencora by 42.1% during the first quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock worth $1,281,429,000 after acquiring an additional 1,364,433 shares during the period. Finally, Goldman Sachs Group Inc. raised its position in Cencora by 9.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,711,281 shares of the company’s stock worth $475,890,000 after acquiring an additional 154,311 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Stock Down 0.0%

Shares of Cencora stock opened at $294.82 on Thursday. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. The business’s 50 day simple moving average is $293.06 and its 200-day simple moving average is $282.92. The stock has a market capitalization of $57.16 billion, a price-to-earnings ratio of 30.33, a PEG ratio of 1.38 and a beta of 0.62. Cencora, Inc. has a twelve month low of $218.65 and a twelve month high of $309.35.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.79 by $0.21. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business had revenue of $80.66 billion during the quarter, compared to analyst estimates of $80.34 billion. During the same period in the prior year, the company posted $3.34 EPS. The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. Equities research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Friday, August 15th were issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 15th. Cencora’s dividend payout ratio is 22.63%.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Wells Fargo & Company increased their price target on shares of Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a report on Wednesday, August 13th. Morgan Stanley set a $330.00 price target on shares of Cencora and gave the company an “equal weight” rating in a research report on Wednesday, July 16th. Jefferies Financial Group lifted their price objective on Cencora from $275.00 to $300.00 and gave the stock a “hold” rating in a research report on Monday, June 30th. Citigroup boosted their price target on Cencora from $330.00 to $355.00 and gave the company a “buy” rating in a report on Thursday, May 8th. Finally, Robert W. Baird lifted their price objective on Cencora from $314.00 to $350.00 and gave the company an “outperform” rating in a research report on Thursday, May 8th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, Cencora presently has an average rating of “Moderate Buy” and an average price target of $311.25.

Insider Buying and Selling

In other Cencora news, CEO Robert P. Mauch sold 4,968 shares of the stock in a transaction on Friday, July 18th. The stock was sold at an average price of $294.11, for a total transaction of $1,461,138.48. Following the completion of the transaction, the chief executive officer directly owned 42,351 shares of the company’s stock, valued at approximately $12,455,852.61. This trade represents a 10.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Chairman Steven H. Collis sold 14,579 shares of the stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $292.62, for a total value of $4,266,106.98. Following the transaction, the chairman directly owned 311,913 shares of the company’s stock, valued at approximately $91,271,982.06. The trade was a 4.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 34,125 shares of company stock valued at $9,993,789 over the last three months. Corporate insiders own 10.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.